On August 11, 2022, Silence Therapeutics plc (the "Company") reported that entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. relating to an underwritten offering (the "Offering") of 5,950,000 American Depositary Shares (the "ADSs"), each representing three ordinary shares, nominal value £0.05 per share in the capital of the Company (the "Underlying Shares") (Filing, 6-K, Silence Therapeutics, AUG 11, 2022, View Source [SID1234618431]). The Offering was priced at $9.50 per ADS, for aggregate gross proceeds to the Company of approximately $56.5 million, before deducting underwriting discounts and commissions and other offering expenses. The Offering closed on August 16, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ADSs were issued pursuant to a shelf registration statement on Form F-3 that was filed with the Securities and Exchange Commission ("SEC") on October 15, 2021 and declared effective by the SEC on October 22, 2021 (File No. 333-260265). A prospectus supplement relating to the Offering has been filed with the SEC.
In the Underwriting Agreement, the Company makes customary representations, warranties and covenants and also agrees to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the underwriters may be required to make because of such liabilities. The foregoing descriptions of the terms of the Underwriting Agreement are qualified in their entirety by reference to the full text of the Underwriting Agreement, a copy of which is attached as Exhibit 1.1 hereto and is herein incorporated by reference.
A copy of the legal opinion and consent of Cooley (UK) LLP relating to the ADSs and the Underlying Shares is filed as Exhibit 5.1 to this Form 6-K and incorporated by reference herein.
This Report on Form 6-K (including Exhibits 1.1, 5.1 and 23.1) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-260265) of Silence Therapeutics plc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
This Report on Form 6-K (excluding Exhibits 1.1, 5.1 and 23.1) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-248682) and Form F-3 (File No. 333-248203) of Silence Therapeutics plc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.